Company profile: Relay Therapeutics
1.1 - Company Overview
Company description
- Provider of an allosteric drug-discovery platform applying computational techniques to protein motion. Offers the Dynamo Platform integrating experimental and computational methods on protein dynamics and a pipeline in precision oncology and genetic diseases, including RLY-4008 (FGFR2), RLY-2608 (pan mutant-selective PI3Kα), and RLY-1971 (SHP2), all in early clinical development.
Products and services
- Dynamo Platform: Research-grade system integrating experimental and computational techniques to interrogate protein dynamics, enabling identification and optimization of therapeutic candidates in allosteric drug discovery
- RLY-4008: Investigational therapy engineered to target FGFR2 alterations in advanced solid tumors, progressing through early clinical trials
- Pipeline: Portfolio-scale collection of therapeutic candidates in various development stages, primarily targeting precision oncology and genetic diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Relay Therapeutics
Calistoga Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutic oral medicines targeting selected isoforms of the PI3K pathway to improve the health of patients with cancer and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calistoga Pharmaceuticals company profile →
Tilt Biotherapeutics
HQ: Finland
Website
- Description: Provider of oncolytic viral cancer immunotherapies that enable tumor T-cell therapy by modifying the tumor microenvironment. Pipeline includes TILT-123 (cytokine-armed oncolytic adenovirus, in Phase 1), TILT-234 (Ad3 armed with human CD40L, ready for CMC/regulatory), TILT-321/322 (bispecific antibody-coding adenoviruses, discovery), and TILT-452 (preclinical), with clinical trial collaborations on TILT-123 with Merck KGaA and MSD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tilt Biotherapeutics company profile →
Biofidelity
HQ: United Kingdom
Website
- Description: Provider of molecular diagnostic assays and platforms for rapid detection of target DNA sequences and actionable genomic biomarkers, with applications in oncology, prenatal testing, and infectious disease. Products include ASPYRE-Lung for guideline-recommended lung cancer biomarkers with results in days, and ASPYRE, a chemistry platform usable on existing PCR instruments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biofidelity company profile →
IsoRay
HQ: United States
Website
- Description: Provider of state-of-the-art, personalized brachytherapy products that offer more cost-effective cancer treatment, utilizing a unique isotope for the treatment of both common and difficult-to-treat cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IsoRay company profile →
Avacta
HQ: United Kingdom
Website
- Description: Provider of technologies, consumables and reagents for life science markets from drug discovery to diagnostics; engaged in research, development, production and delivery of instrumentation and services for biopharmaceutical drug development and clinical diagnostics using biophysical technology. Offerings include the pre|CISION Platform, Affimer Technology, AVA6000, Launch Diagnostics (UK/France), and Coris Bioconcept rapid diagnostic test kits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avacta company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Relay Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Relay Therapeutics
2.2 - Growth funds investing in similar companies to Relay Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Relay Therapeutics
4.2 - Public trading comparable groups for Relay Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →